Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 9/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | IL4I1 | Q96RQ9 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL849483 | 0.84 | FOLH1 (0.59) | MRGPRX4ALDH1A1 | |
| SCHEMBL9917299 | 0.84 | MAOB (0.49) | MAOBMAOAIL4I1MRGPRX4ALDH1A1 | |
| SCHEMBL28316824 | 0.82 | PARP1 (0.52) | MAOBMAOAMRGPRX4 | |
| SCHEMBL10144968 | 0.81 | LOXL2 (0.64) | MRGPRX4ALDH1A1HPGD | |
| SCHEMBL22867774 | 0.81 | ATM (0.57) | MRGPRX4ALDH1A1 | |
| SCHEMBL7637125 | 0.79 | MAOB (0.51) | MAOBMAOAIL4I1MRGPRX4ALDH1A1 | |
| SCHEMBL3335985 | 0.79 | LMNA (0.59) | MAOBMAOAIL4I1MRGPRX4ALDH1A1 | |
| SCHEMBL27981636 | 0.78 | LOXL2 (0.44) | MRGPRX4ALDH1A1LMNA | |
| SCHEMBL27944407 | 0.78 | LOXL2 (0.44) | MRGPRX4ALDH1A1LMNA | |
| SCHEMBL4958280 | 0.78 | KAT6A (0.51) | MAOBMAOAIL4I1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814380-B2 | Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-11-14 | — | — | US | disclosed |
| US-11814380-B2 | Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-11-14 | — | — | US | disclosed |
| EP-4219493-A1 | BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2023-08-02 | — | — | EP | disclosed |
| EP-3728254-B1 | BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2023-02-15 | — | — | EP | disclosed |
| US-20220081423-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2022-03-17 | — | — | US | disclosed |
| US-11028075-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-20210009588-A1 | NOVEL BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-01-14 | — | — | US | disclosed |
| EP-3759098-A1 | PYRIDINE-SULFONAMIDE COMPOUNDS AND THEIR USE AGAINST PAIN AND RELATED CONDITIONS | Genentech, Inc. (US) | 2021-01-06 | — | — | EP | disclosed |
| WO-2020254451-A1 | ANTICANCER COMBINATION THERAPY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-12-24 | — | — | WO | disclosed |
| US-10829487-B2 | Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-11-10 | — | — | US | disclosed |
| US-20190263786-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-08-29 | — | — | US | disclosed |
| WO-2019165290-A1 | PYRIDINE-SULFONAMIDE COMPOUNDS AND THEIR USE AGAINST PAIN AND RELATED CONDITIONS | GENENTECH, INC. (US) | 2019-08-29 | — | — | WO | disclosed |
| US-20190194192-A1 | NOVEL BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-06-27 | — | — | US | disclosed |
| EP-2559730-A1 | PROCESS FOR PRODUCING FLUORINE-CONTAINING COPOLYMER COMPOSITION AND FLUOROCARBON-RESIN MOLDED PRODUCT | Asahi Glass Company, Limited (JP) | 2013-02-20 | — | — | EP | disclosed |
| US-20130041109-A1 | PROCESS FOR PRODUCING FLUORINATED COPOLYMER COMPOSITION AND FLUORORESIN MOLDED PRODUCT | ASAHI GLASS COMPANY, LIMITED (JP) | 2013-02-14 | — | — | US | disclosed |
| EP-2508564-A1 | PROCESS FOR PRODUCING FLUOROCOPOLYMER NANOCOMPOSITE | Asahi Glass Company, Limited (JP) | 2012-10-10 | — | — | EP | disclosed |
| US-20120232207-A1 | PROCESS FOR PRODUCING FLUORINATED COPOLYMER NANOCOMPOSITE | ASAHI GLASS COMPANY, LIMITED (JP) | 2012-09-13 | — | — | US | disclosed |
| JP-2006221936-A | ELECTROLYTE AND BATTERY | SONY CORP | 2006-08-24 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263786-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | ASAH2, ACER2, PCSK9 | MAOB 1656/4885EPHX1 1567/4885MAOA 2521/4885 |
| US-20220081423-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | TRPV1, HCN4, TRPA1 | MAOB 1125/4885EPHX1 1493/4885MAOA 2896/4885 |
| US-20210009588-A1 | NOVEL BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS | SOS1, SOST, SOS2 | MAOB 1863/4885EPHX1 838/4885MAOA 2513/4885 |
| US-11814380-B2 | Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors | SOS1, SOST, BMP1 | MAOB 1540/4885EPHX1 931/4885MAOA 2118/4885 |
| US-20190194192-A1 | NOVEL BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS | SOS1, SOST, SOS2 | MAOB 1841/4885EPHX1 853/4885MAOA 2505/4885 |
| US-11028075-B2 | Therapeutic compounds and methods of use thereof | TRPV1, HCN4, TRPA1 | MAOB 1125/4885EPHX1 1493/4885MAOA 2896/4885 |
| US-10829487-B2 | Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors | SOS1, SOST, BMP1 | MAOB 1492/4885EPHX1 958/4885MAOA 2105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.